World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 3 April 2023
Main ID:  NCT02870738
Date of registration: 12/08/2016
Prospective Registration: Yes
Primary sponsor: William Beaumont Hospitals
Public title: Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
Scientific title: Comparison of Bladder Directed and Pelvic Floor Therapy in Women With Interstitial Cystitis/Bladder Pain Syndrome
Date of first enrolment: April 21, 2017
Target sample size: 128
Recruitment status: Recruiting
URL:  https://clinicaltrials.gov/show/NCT02870738
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).  
Phase:  Phase 2
Countries of recruitment
United States
Contacts
Name:     Lydia Kosovich, RN
Address: 
Telephone: 248-551-3291
Email: Lydia.Kosovich@Beaumont.org
Affiliation: 
Name:     Kenneth M Peters, MD
Address: 
Telephone:
Email:
Affiliation:  Beaumont Hospital-Royal Oak
Name:     Kenneth M Peters, MD
Address: 
Telephone:
Email: kmpeters@beaumont.edu
Affiliation: 
Key inclusion & exclusion criteria

Inclusion Criteria:

- Female

- Age 18 to 85 years

- History of patient self-reported of IC/BPS symptoms for at least 6 months.

- Using an approved method of birth control, or surgically sterile, or of non-child
bearing age with no menstrual period for the past 12 months

- Must be willing to not start any new medication known to affect bladder or muscle
function, and to ideally remain on a stable dose of all other medications through the
secondary endpoint.

Exclusion Criteria:

- Active urethral or ureteral calculi, urethral diverticulum, history of pelvic
radiation therapy, tuberculous cystitis, bladder cancer, carcinoma in situ (bladder),
urethral cancer

- Hunner's lesions found on screening cystoscopy

- Prior investigational or therapeutic bladder instillations for IC/BPS symptoms within
the past 3 months

- Lactation, pregnancy, or refusal of medically approved/reliable birth control in women
of child-bearing potential.

- Pain, frequency, and/or urgency symptoms only present during menses

- Clinically confirmed urinary tract infection at time of screening

- Participant unable to tolerate insertion of one or two vaginal examining fingers (e.g.
Vulvar allodynia)

- Participant had prior course of physical therapy (PT) that included internal (vaginal
and/or rectal) manual therapy with connective tissue manipulation by physical
therapist for the same symptoms within the past 3 months (prior treatment by therapist
with biofeedback, electrical stimulation, or pelvic floor exercises is not
exclusionary)

- Participant in the opinion of the investigator has a relevant neurologic disorder that
affects bladder and/or neuromuscular function

- Participant has/reports any severe, debilitating or urgent concurrent, medical
condition

- Participant has a potentially significant pelvic pathology or abnormality on
examination or prior imaging, including prolapse beyond the hymenal ring, pelvic mass,
etc., that in the investigators' judgment, could cause or contribute to the clinical
symptoms, or require treatment

- Any other condition which, in the investigator's judgment, may increase risk to
subject's welfare

- Participation in an investigational trial that uses a study treatment less than 6
months from the date of the screening visit

Note: For the sake of preserving scientific integrity, one or more of the eligibility
criteria have been left off the list posted while the trial is ongoing. A full list of
eligibility criteria will be posted upon completion of the trial.



Age minimum: 18 Years
Age maximum: 85 Years
Gender: Female
Health Condition(s) or Problem(s) studied
Painful Bladder Syndrome
Cystitis, Interstitial
Intervention(s)
Drug: Bladder Instillations
Procedure: Pelvic Floor Physical Therapy
Primary Outcome(s)
Markedly/Moderately Improved on Global Response Assessments [Time Frame: Week 9 (one week after last treatment)]
Secondary Outcome(s)
Change in symptoms [Time Frame: Week 9 (one week after last treatment)]
Secondary ID(s)
2016-253
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Baylor College of Medicine
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history